As first line therapy, DPP-4 inhibitors can be an alternative therapeutic option in patients who cannot tolerate metformin because of gastrointestinal adverse events, and several clinical studies have proved their efficacy as monotherapy in drug-naïve patients with diabetes type 2. Here, DPP4 is linked to type 2 diabetes mellitus.